Health Check: After decades of investor pain, Mesoblast faces ‘extraordinary
A year after its maiden product launch, Mesoblast is at a “defining and transformative point”EBR Systems sees green shoots after soft sales periodSyntara shares swoon after study setbackBiotech investors are realising…

- A year after its maiden product launch, Mesoblast is at a “defining and transformative point”
- EBR Systems sees green shoots after soft sales period
- Syntara shares swoon after study setback
Biotech investors are realising that successful trial results and even regulatory approvals do not guarantee commercial success – and this applies to drug, device and diagnostic developers.
However, two leading US-focused companies today foreshadowed better fortunes after difficult periods.
At Mesoblast’s (ASX:MSB) AGM, chairman Phil Facchina said the stem-cell developer was at a “defining and transformative point”, as it turned from a strict R&D focus to commercial rollout.
The company began selling its first product, the paediatric graft-versus-host disease treatment Ryoncil, in late 2025. The US Food & Drug Administration (FDA) approved the therapy in late 2024.
Ryoncil generated US$115 million of sales in the 2025-26 year.
“We are transitioning from a company whose value had been driven exclusively by its scientific progress and the potential of its clinical pipeline to one that must increasingly be focused on commercial execution,” Facchina told holders.
“This transition represents both an extraordinary opportunity and a fundamental change in how Mesoblast operates, executes and measures its success.”
‘First of many’
Mesoblast hopes the FDA’s breakthrough assent will pave the way for other products.
On that note, Facchina said the company had completed enrolment for its pivotal phase III study of rexlemestrocel-L to treat chronic low back pain.
The company also has started enrolling for its registrational trial to expand Ryoncil to the adult population – a bigger indication.
Further down the evolutionary scale, Mesoblast continues to work on a chronic heart failure remedy.
Mesoblast’s commercial evolution took more than two decades and involved buckets of money and frequent setbacks. As of June this year the company carried US$1.068 billion ($1.5bn) of accumulated losses.
“Over many years, the company’s efforts have required extraordinary perseverance, significant financial resources, and an unwavering belief in the potential of its technology,” Facchina said.
Despite the upbeat vibes, Mesoblast shares have declined 7% over the last 12 months.
In this market, investors take no prisoners.
EBR reports improvement green shoots
After slower-than-expected sales of its Wise heart device in its pilot US rollout, EBR Systems (ASX:EBR) reports “positive early results” in the December quarter.
In a US filing, EBR today disclosed September quarter receipts of US$2.134 million, off the pace from US$3.618m in the June quarter but better than the March stanza tally of US$1.3m.
The company reported net cash outflows of US$17.25m, steady on the June quarter and better than the March quarter’s US$20.25m deficit.
EBR ended the quarter with cash and equivalents of US$95m ($137m). The company raised $150m in early June.
Affirming a previous update, EBR said surgeons had implanted 40 Wise devices commercially during the quarter. This takes the total commercial implants across the pilot launch phase to 157.
During the quarter the company trained 10 physicians in the use of Wise, taking the total number of qualified docs to 100.
Management acknowledged sales had not been up to scratch in the month of September, reaching only half the average monthly volume recorded in July and August.
As a result, EBR has ‘realigned’ its commercial structure, with the chief commercial officer departing and CEO John McCutcheon becoming responsible for sales pending a replacement.
Along with exec chairman Allan Wills, McCutcheon has taken to the ‘hustings’ in a flurry of client field visits.
EBR “remains focused on improving commercial productivity and converting its growing base of trained physicians, activated accounts and purchasing access into more consistent procedural activity over time.”
Management did not quantify the December quarter improvement, but was due to brief investors at noon Australian time.
Syntara suspends skin scarring study
As if local investors need any more evidence of the difficulty of executing a drug trial, Syntara (ASX:SNT) has provided it.
The company today said it had paused recruitment of its Phase 1b study of SNT-9465, for hypertrophic scars after sternotomy surgery.
This followed an internal review of the blinded study population.
“After receiving reports of mild to moderate skin irritation in some patients, recruitment has now been paused to allow a thorough review of unblinded data from completed and ongoing patients.”
The company will then decide either to recommence recruitment or discontinue the study.
On October 1 Syntara said it had expanded the trial from 20 to 30 patients, with topline results due in the March 2027 quarter.
“The feedback received from patients and trial sites during the study supported our decision to expand recruitment and open an additional clinical site to meet recruitment timelines,” CEO Gary Phillips said.
“However, the emergence of tolerability issues in this blinded study population requires us to now pause recruitment and analyse the available data before progressing further.”
Not the main game
SNT-9465 seeks to inhibit the pan-lysyl oxidase, an enzyme closely implicated in inflammation and fibrosis.
We should stress that SNT-9465 is not Syntara’s main game. The company’s flagship effort is SNT-5505, for myelofibrosis.
In August last year Syntara shares halved after the FDA insisted on a separate phase IIb myelofibrosis trial, as lead into a registration phase III effort.
The company had angled for an all-in-one adaptive phase II/III effort.
At the time, Phillips said the share response was a tad overdone, as the “pathway forward” was unchanged.
However, the study will take longer – and that was enough to spook trigger-happy investors.
Given that sell-off, surely Syntara shares couldn’t be flogged again?
Yes, actually: the stock lost up to 4 cents or 21% this morning.
AI to the rescue?
Can AI salvage Paradigm Biopharmaceuticals’ (ASX:PAR) stalled knee osteoarthritis program?
In September, the company discontinued its phase III trial after discovering large slabs of missing clinical data.
By the end of the month the company was in voluntary administration, pending a review of what went wrong.
Today, Pathkey.AI (ASX:PKY) said it had signed an agreement with Paradigm to evaluate the study independently with its bots.
Pathkey’s Trialkey platform will assess whether “changes to study design, conduct or analysis could have affected the interim result”.
The job is worth $25,000.
While Paradigm’s administrators don’t endorse the Trialkey platform, it’s heartening that they are willing to fund a moonshot attempt to revive the program.
At Stockhead, we tell it as it is. While EBR is a Stockhead advertiser, the company did not sponsor this article.
The post Health Check: After decades of investor pain, Mesoblast faces ‘extraordinary opportunity’ appeared first on Stockhead.
Figures reflect the source report and its stated period. This article is for information and is not investment advice.



